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ABSTRACT 
 
Branched Chain Amino Acids: Causal or Predictive of Type 2 Diabetes 
 
By 
 
Jency Annie George 
 
6/13/2017 
 
 
 
Branched Chain Amino Acids (BCAA) have been associated with insulin resistance and type 2 
diabetes. However, there is not concrete understanding on whether BCAA is playing a causal 
factor or a predictive factor for type 2 diabetes. The aim of this review is to understand how 
Branched Chain Amino Acids act as a predictive biomarker of type 2 diabetes (T2D) or causal 
factor in insulin resistance.  Two mechanisms have been proposed, but not enough studies have 
been done to prove which is true. There is still a lot of unknowns in BCAA mechanisms and how 
it affects metabolic disorders. Future study recommendations have been made to further 
understand BCAA pertaining to T2D and other metabolic disorders. After reviewing current 
studies, there is not enough evidence to confirm whether BCAAs are causative or predictive of 
T2D. 
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Chapter 1: Background 
1.1 Branched Chain Amino Acids 
Branched Chain Amino Acids (BCAAs), specifically Leucine, Isoleucine, and Valine, are 
essential amino acids that are required for normal functioning. They are the building blocks for 
proteins, and therefore, are important in tissue expansion and regeneration as well as having 
metabolic functions. Recently, BCAAs have been used in performance enhancements for 
exercise. BCAAs also increase the secretion of insulin (1,2). An increase in circulating BCAAs has 
been associated with insulin resistance and type 2 diabetes (1,2). BCAAs are potentially a 
biomarker, rather than a causative factor of insulin resistance because insulin resistance 
increases the appearance rate of BCAAs and is linked to the reduced expression of 
mitochondrial BCAA catabolic enzymes (1,3). The aim of this review is to understand how 
Branched Chain Amino Acids act as a predictive biomarker of type 2 diabetes (T2D) or causal 
factor in insulin resistance.  
It is known that the build-up of BCAA by-products can affect insulin sensitivity, but do 
the by-products blunt other metabolic pathways and potentially cause other metabolic 
disorders? Acylcarnitines are the connecting factor between BCAA and insulin resistance. 
Acetyl-CoA and propionyl-CoA, which are important components of the TCA cycle, which also 
creates by-products like C3-acylcarnitine and C5-acylcarnitines (4). C3 and C5 have been found 
to be involved in insulin administration.  Acylcarnitines have only been studied regarding insulin 
resistance, and not many studies have determined whether they play a role in other metabolic 
disorders. It has been suggested that fatty acid oxidation, which yields energy, maybe be a 
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factor that leads to the accumulation of acylcarnitines via the TCA cycle (4). The metabolic by-
products create more controversy regarding whether BCAAs are a causal factor with respect to 
T2D and insulin resistance. 
1.2 Diabetes 
Diabetes is a metabolic disorder with multiple etiologies characterized by chronic 
hyperglycemia with disturbances in carbohydrate, fat and protein metabolism that result from 
defects in insulin secretion, activity or both. Diabetes is the most common endocrine problem 
worldwide, with the incidence rate growing at an alarming rate and causing it to be the seventh 
leading cause of death. Roughly 90% of individuals with diabetes in the United States have type 
2 diabetes. Many complications coincide with diabetes, such as high blood pressure, 
cardiovascular disease, stroke, and blindness (5). The CDC (6) states that 29.1 million people 
currently have diabetes across all age groups, including 21.0 million individuals who have been 
diagnosed with diabetes and 8.1 million people are undiagnosed. The National Health and 
Nutrition Examination Survey (NHANES) has permitted the ability to gather percentages of 
diabetic people in the United States. By collecting both fasting glucose and hemoglobin A1C 
levels, the data from the survey allow estimates of the percentage of undiagnosed diabetics 
and prediabetic individuals. In a 2014 report by the CDC, American Indians/Alaskan Natives had 
the highest age-adjusted percentage of people 20 years or older with diagnosed diabetes at 
15.9%, while Non-Hispanic blacks were the second highest with 13.2%. Obesity has been 
observed as a contributing factor to diabetes. Approximately 85.2% of overweight adults older 
than 20 have been previously diagnosed with diabetes, and 54.8% of obese adults are diabetic 
(5, 6). 
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Individuals with type 2 diabetes manage their glucose levels by following a healthy meal 
plan, participating in the exercise along with weight loss, as well as taking medications. Insulin is 
commonly used to control glucose levels in those who have type 2 diabetes (5,6). Insulin is a 
hormone that is secreted when circulating glucose levels rise from the digestion of 
carbohydrates. Insulin triggers the absorption of glucose from the blood stream into cells. 
Individuals become insulin-resistant when tissues absorbing glucose do not properly respond to 
secreted insulin, and thus, blood glucose levels become abnormally high (7). Insulin resistance 
is a physiological condition in which target organs fail to respond to the insulin effectively. 
Issues in insulin response impair the use of these target organs leading to the development of 
type 2 diabetes (8). Insulin resistance that is not controlled by individuals that have diabetes 
mellitus can results in muscle protein degradation, though this can be improved upon 
treatment with insulin. 
1.3 Insulin Signaling Pathway  
Many factors coincide with obesity and play a role in the development of type 2 
diabetes (7). Adipokines are peptide hormones or cytokines that are produced and secreted by 
adipocytes, which play a part in the development of insulin resistance, and have the capacity to 
store excess lipids that become saturated during obesity, leading to the abnormal redistribution 
of lipids to organs and tissues. Adipose tissue exhibits insulin resistance through the cytokine-
related molecule leptin. Further studies have also revealed that adipose cells produce 
adiponectin, retinol-binding protein-4, resistin, and proinflammatory cytokines. Leptin and 
adiponectin decrease triglyceride synthesis, which stimulates β-oxidation and increases insulin 
action in skeletal muscle and the liver.  Inflammatory mediators may also lead to insulin 
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resistance (7). Insulin resistance is partly caused by changes in hormone and cytokine 
production by the liver, adipose tissue and immune cells in response to the chronic exposure to 
lipids (7, 8). 
When insulin binds to the insulin receptor, it leads to autophosphorylation of the insulin 
receptor and promotes the binding of scaffold proteins, including insulin receptor substrate 
proteins, Src-homology-2- containing protein and the c-Cbl proto-oncogene (7). 
Phosphorylation of the scaffolding proteins engages various pathways in insulin signaling. The 
insulin receptor substrate 1 is the key mediator of insulin-stimulated glucose uptake and 
activation of anabolic pathways in muscle and adipose tissue. This insulin activity promotes 
glucose uptake and storage but can be attenuated by other regulators (7,8,9). Pathways 
initiation can be reversed by the protein Tyr phosphatase-1B (PTB1B) and insulin receptor Tyr 
kinase activity (7). 
There are possible fundamental changes in metabolism that occur in response to over-
nutrition. For example, lipid-derived metabolites accumulate outside the adipose depots in 
response to a high-fat diet (7,9,10). The accumulation of the metabolites leads to metabolic 
overload that causes a potential loss of insulin sensitivity. In the liver, chronic increases in 
malonyl coenzyme A levels promote de novo fatty synthesis and inhibit carnitine 
palmitoyltransferas-1 (CPT1) activity. Long chain-CoAs are diverted away from mitochondrial 
oxidation towards biosynthetic enzymes that produce triglycerides and signaling intermediates. 
Over-nutrition imposes an anabolic burden on the endoplasmic reticulum, which causes protein 
misfolding and activation of inositol-requiring kinase-1 (IRE1). These adverse events converge 
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on stress-induced Ser kinases that impede insulin-mediated suppression of gluconeogenesis 
while allowing lipid synthesis and restricting β-oxidation (7). 
In skeletal muscle, over-nutrition stimulates fatty acid influx, and PPARα/δ-mediated 
activation of target genes promote β -oxidation without a coordinated increase in TCA cycle 
flux. This results in incomplete fat oxidation metabolic by-products, such as acyl carnitines, 
which are BCAA-derived, and ROS, which accumulates in the mitochondria. These by-products 
might activate Ser kinases that impede insulin signaling and glucose transporter-4 (GLUT4) 
translocation (7,10). Exercise has been shown to reduce lipid stress by increasing TCA cycle flux 
by coupling the ligand-induced PPARα/δ activity with PPARyco-activator-1α (PGC1α)-mediated 
remodeling of downstream metabolic pathways (7). 
Obesity can also lead to insulin resistance (1,5,7,9); however, not all obesity-related 
insulin resistance progresses to type 2 diabetes. β-cell failure involves a decrease in β-cell mass 
and deterioration of glucose-stimulated insulin secretion (GSIS) (7). Insulin secretion from islet 
cells is stimulated by glucose metabolism, which leads to an increase in the ATP: ADP ratio and 
closure of the ATP-sensitive K+ channel-dependent mechanism. This activates voltage-gated 
Ca2+ channels, which creates an influx of Ca2+ and stimulates insulin granule exocytosis. The 
failure of β-cells in type 2 diabetes could be caused by mitochondrial metabolic overload, 
endoplasmic reticulum stress and the deposition of harmful amyloid fibrils (7,9). As stated 
before, over-nutrition induces an increase in the lipid supply, resulting in the induction β-
oxidation enzymes such as CPT1 (7,9,10). This increases acetyl-CoA levels, allosteric activation 
of pyruvate carboxylase and upregulation of pyruvate cycling, which ultimately blunts GSIS. 
Pyruvate cycling involves the entry of pyruvate or other substrates into the tricarboxylic acid 
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cycle to generate excess intermediates that exit the mitochondria and engage in different 
cytosolic pathways that eventually lead back to pyruvate. This increases the demand for insulin 
biosynthesis, which results in increased ER stress and protein misfolding (7,11). 
 
1.4 BCAA Metabolic Pathway and Mechanisms 
The BCAA metabolic pathway crosses with the mechanism for insulin resistance. The 
first step in BCAA metabolism takes place in the peripheral tissue, except the liver, and is 
catalyzed by the mitochondrial isoform of branched-chain-amino-acid transaminase (BCAT(m)), 
which is encoded by the BCAT2 gene. The deletion of the BCAT2 gene prevents BCAA 
metabolites from forming in peripheral tissues. When BCAT2 is present, BCAAs are converted 
into branched-chain α-ketoacids via the removal of the amino groups. Next, the α-ketoacids are 
decarboxylated by branched-chain α-ketoacid dehydrogenase (BCKD). Finally, the BCAA 
metabolites are catabolized by a series of enzyme reactions to their final products, acetyl-CoA, 
and succinyl-CoA, which enter the TCA cycle (2,3,11,12). 
There are two hypothesized mechanisms that play a role in insulin resistance and type 2 
diabetes. The first mechanism is activated by elevated BCAA levels resulting in insulin resistance 
in the phosphorylation of insulin receptor substrate 1. mTORC1 is a serine/threonine kinase 
that regulates important cellular and developmental processes (2,3,12,13). mTORC1 promotes 
insulin resistance through serine phosphorylation of insulin receptor substrates (IRS)-1 and IRS-
2, which increases inflammation and the demand for insulin due to the impaired insulin activity.  
The rate of protein degradation in muscle can be inhibited by insulin and insulin-like growth 
factor 1 (2,3,12,13). Though there is evidence that supports this mechanism, it is still a 
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controversial mechanism because exercise and BCAA supplementation have been shown to 
improve metabolism, even when mTORC1 is activated (2,3).  
The second proposed mechanism is known as BCAA dysmetabolism. Impairments in BCAA 
metabolism can induce the accumulation of toxic intermediates that impair cellular function(s) 
(3). This model suggests that the accumulation of toxic intermediates, such as increases in 
acylcarnitines and acetyl-CoA, promotes β-cell mitochondrial dysfunction and eventually leads 
to β-cell apoptosis as well as type 2 diabetes, which is observed with elevated BCAA levels 
(3,14). Altered gene expression can be caused by either mutations or epigenetic regulation. 
Tiffen et al. identified BCKDH4, a gene that encodes the regulatory subunit in BCKDC. BCKDC 
activity is impeded by long-chain fatty acids and their metabolites by directly affecting the 
redox state or the concentration of acetyl-CoA or indirectly by inhibiting enzyme carbonylation 
(2,3). 
 
 Chapter 2:  What we know about Insulin Resistance and BCAAs 
Elevated BCAA levels have been shown to improve metabolic parameters, including body 
composition, glycaemia levels, and satiety. For many years, BCAAs have frequently been used 
by body builders as performance-enhancing supplements (2,11). With insulin, BCAA functions 
as an anabolic signal to alter the growth of energy-consuming tissues. Oral supplementation of 
leucine has been shown to alter protein synthesis in rats; however, when given a carbohydrate 
meal, there were no changes in protein synthesis. The supplementation prompted an increase 
in insulin, suggesting that leucine is a direct nutrient signal to induce protein synthesis (2,3,11). 
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Acute exercise has also been shown to have positive effects on metabolism by activating the 
BCKD complex in skeletal muscle, whereas under a regular diet, there was no increase in 
enzyme activity (11).  Both BCAA supplementation and BCAA-rich diets support the dietary 
recommendation for building proteins and have been shown to increase BCAA levels (2,3,11). 
Though BCAAs have been shown to promote positive effects, there is still controversy 
regarding whether elevated BCAA levels can lead to insulin resistance and type 2 diabetes 
(T2D). Individuals with obesity and T2D are often characterized as having increased BCAA levels. 
For example, the study by Fiehn et al. supports the association between a BCAA signature and 
insulin resistance when leucine and valine were increased in African American women with 
T2D. Moreover, longitudinal studies have shown that BCAA levels in the blood can predict the 
likelihood of developing insulin resistance or T2D (2).  Table 1 provides a summary of current 
studies on BCAA, obesity, and T2D. 
2.1 Current Studies 
Newgard et al. discuss the potential cause-effect relationships between BCAAs and 
metabolic diseases, as there are strong associations between BCAAs and metabolites that play a 
role in T2D. When there is an influx of BCAAs, there is a simultaneous increase in BCAA 
catabolism, which enhances the production of propionyl-CoA and succinyl-CoA. This results in 
possible contributions to the incomplete oxidation of fatty acids. Another possibility that is that 
a high-fat diet could cause the substrates involved in BCAA metabolism to overflow the TCA 
cycle; this would contribute to the accumulation of incompletely oxidized fatty acid and BCAA 
oxidation intermediates, which could contribute to insulin resistance. Newgard continues to 
discuss that BCAA levels and the increase in insulin resistance are not completely understood; 
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however, there are several possibilities to explain what might cause their correlation. The first 
possibility is through increased protein consumption, but studies that were previously 
discussed suggest that the relationship between BCAAs with insulin resistance and the risk of 
T2D are not influenced by protein consumption. A second possibility is genetic variations in the 
expression of BCAA enzyme genes that control protein synthesis. Lastly, they hypothesized that 
BCAAs synergize with hyperlipidemia to contribute to developing insulin resistance. Readily 
available glucose and lipid substrates in obesity may decrease the need for amino acid 
catabolism in adipose tissues; however, the mechanism of the increased supply of substrates, 
which causes BCAA catabolism enzyme down-regulation, is not well understood (8). 
Lackey et al. conducted a study on the white adipose tissue (WAT), which is considered 
a player in BCAA metabolism in their study. They tested whether BCKD expression is reduced in 
obese WAT and regulated by metabolic signals. The results found that BCKD expression was 
reduced 35-50% in obesity models and that BCKD component transcripts were significantly 
lower in subcutaneous adipocytes compared to lean Pima Indians. Perturbated metabolic 
signals in WAT, which are observed in insulin resistance and T2D, could put stress on WAT BCAA 
utilization. Though there was a reduced expression of the BCKD complex and other BCAA 
catabolism factors in the obese and insulin-resistant individuals, there is not enough evidence 
to equate to these factors as promoting lower BCAA utilization and catabolism in adipose 
tissue. However, Lackey et al. conclude that obesity is less important than WAT metabolic 
regulators in BCAA catabolism (15). 
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Excess BCAAs can promote the development of β-cell dysfunction. Leucine has been found 
to be a principle component associated with insulin resistance by causing a mutation that leads 
to hyperinsulinism. Excess BCAA levels cause a constant secretory pressure on b-cells that can 
contribute to b-cell dysfunction (17,18). Newgard et al. conducted a metabolic profiling study in 
2009 in obese vs. lean humans to discover whether there is a correlation between increased 
BCAA catabolism and insulin resistance. The results showed that insulin resistance is induced by 
high-fat BCAA feeding and associated with chronic mTOR and IRS1 phosphorylation and the 
accumulation of multiple acylcarnitines. In contrast, insulin resistance was reversed by the 
mTOR inhibitor rapamycin. Therefore, they concluded that BCAAs are associated with the 
development of obesity and associated insulin resistance in individuals with poor diet patterns 
that include high-fat consumption (9). 
An interventional study tested whether manipulation of dietary BCAA levels alters fasting 
BCAA levels independent of other factors. In this study, five healthy males were given a low 
BCAA diet for four days followed by a high BCAA diet for four days after a two week period. The 
study found that fasting valine was significantly lower (p=0.02) and the fasting isoleucine and 
leucine were lower in the low BCAA diet compared with the high BCAA diet. The study found 
that short-term manipulation of BCAA intake leads to a modest change in fasting BCAA levels 
(16). 
Lotta et al. studied the genetic predisposition of BCAAs and the risk of T2D in a Mendelian 
randomization analysis; this study examined whether the association is causal by studying 
human genetics and metabolomic pathways in muscle biopsies. The study found that 
participants that genetically predisposition to insulin resistance was associated with higher 
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plasma BCAA levels, which potentially mediate the insulin resistance mechanism. The link 
between insulin resistance and higher BCAA levels is possibly mediated by BCKD activation; this 
has also been suggested by other studies (Ref). Other studies have stated that BCAAs are not a 
causal factor for insulin resistance, rather a biomarker that can lead to insulin resistance or T2D 
(17).  
Obesity and T2D are drastically increasing in children in the United States, with nearly one-
third of children being either overweight or obese. SEARCH for diabetes in youth is a national 
multicenter study that has aimed to understand more about diabetes among children and 
young adults in the United States. The study began in 2000 and is following children until 2020, 
with funding from the CDC and NIH. To date, they have found that there are 1.82 cases of 
diabetes per 1000 youth, with an average of 56 months of diabetes. Hispanic and Asian Pacific 
Islanders have the highest prevalence of diabetes compared to other races (5,18,19). There 
have been internet-delivered interventions that help families receive education about 
treatment and prevention options to reduce the risk of obesity and diabetes. With regards to 
BCAAs, most of the research conducted is performed on middle-aged populations and not in 
younger adult populations (18,19). 
Another interventional study suggests that there are predictors for insulin resistance 
and suggestions for treatment. Shah et al. conducted a study in 2011 in the United States to 
identify biomarkers that predict changes in insulin resistance in regards weight loss. The study 
population was the weight loss management (WLM) clinical trial that aimed at determining the 
effects of two different weight loss interventions compared to a control group. Phase 1 
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included 1,685 participants who had behavioral interventions for six months, followed by the 
collection of fasting blood samples. The participants who lost over 4 kg were randomized into 
phase 2 of the study, which only included 500 participants. BCAA levels were measured via 
mass spectrometry, and insulin resistance was calculated from HOMA-IR. The study found a 
mean weight loss of 8.67±4.28 kg, with a mean HOMA-IR difference of -0.80±1.73 in phase 2. 
After performing principal component analysis, BCAAs and associated catabolites were shown 
to correlate with IR at baseline (r = 0.50, p<0.001) and be independently associated with the 
differences in the HOMA-IR at the 6-month follow-up (r=0.28, p<0.0001). Weight loss itself only 
moderately correlated with the differences in HOMA-IR, which suggests that BCAA catabolites 
are predictors of changes in HOMA-IR. The study concluded that BCAA metabolism is associated 
with IR in non-diabetic obese individuals and can predict improvements in IR with moderate 
weight loss independent of the amount of weight lost (20). 
 Lips et al. observed an association between obesity and T2D with increased BCAA levels. 
Their study was conducted in the Netherlands in 2013 to observe whether plasma BCAA levels 
are reduced in obese women independent of weight loss or the presence of T2D. The study 
included 30 obese non-diabetic participants, 32 obese T2D participants, and 12 lean female 
subjects. The obese women underwent restrictive procedures such as gastric binding or the 
restrictive/bypass via Roux-en-Y-Gastric Bypass surgery. Fasting blood samples were drawn four 
weeks before and three weeks and three months after the intervention. This interventional 
study found that plasma BCAA levels were higher in the T2D patients compared with the 
normal non-diabetic and lean subjects. There were no specific amino acids that were affected 
by weight loss through the gastric bypass in the normal glucose tolerant (NGT) subjects 
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However, NGT subjects that had the RYGB surgery displayed a decrease in amino acids (Leucine 
P=2.3x10-5, Valine P= 3.1x 10-7) in a mixed-model analysis. BCAA levels were also correlated 
with insulin sensitivity and glucose tolerance. The study concluded that there is a significant 
decrease in BCAAs 3 weeks after the procedure. However, after three months, the bypass 
procedure reduced BCAA levels in the obese subjects independent of weight-loss or T2D. This 
study does not justify whether the surgeries are what caused the decrease in circulating BCAA 
levels. Calorie restriction has a similar effect on insulin sensitivity and glucose tolerance without 
affecting BCAA levels, though a reduction in BCAA levels is not necessary for improvements in 
obesity-associated insulin resistance (21). 
The study by Qin et al. was conducted within the International Study of 
Macro/Micronutrients and Blood Pressure and examined various cross-sectional relationships 
between dietary BCAA intake and body weight status/obesity in China, Japan, the United 
Kingdom and the United States. By involving many different countries, inferences pertaining to 
lifestyle, ethnicity and cultural backgrounds can be shown to play a distinct role in BCAA 
metabolism and obesity. The study included 4,429 diabetes-free overweight and obese 
participants with the objective being to determine whether there was an association between 
dietary BCAA intake and obesity. The levels of BCAAs and other nutrients were determined 
from urine tests. Participants' diets were observed through 4 multi-pass 24 hour recalls, and the 
measurements of dietary BCAAs were derived from country-specific food tables.  After 
performing ANOVA and chi-square tests to compare the data across 4 BCAA quartiles, the 
authors found that the mean BCAA intake was 2.6± 0.6% energy, which is equivalent to the 
total protein intake. The BCAA intake was observed to be significantly lower in the Chinese 
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population compared to the populations from the other countries. The multivariable-adjusted 
OR for the association between BCAA intake and the overweight quartiles with the 1st quartile 
being a reference category are as follows: (1) 2nd quartile - 0.97 (0.80-1.17), (2) 3rd quartile - 
0.91 (0.75-1,11), and (3) 4th quartile - 0.70 (0.57-0.86). The BCAA intake was inverse with 
associated with the prevalence of obesity (P-trend = 0.03), suggesting that a higher BCAA 
dietary intake may reduce the prevalence of overweight/obese status among healthy 
individuals from East Asian and Western countries (22).   
Li et al. did a study by specifically observing young adults. This study was conducted in China 
in 2014 and observed the association between the ratio of BCAA intake and the risk of obesity 
among young people in an Internet-based cross-sectional study. There was a total of 948 
randomly selected participants who were asked to finish an internet-based questionnaire that 
asked about their diet. Ninety of the participants were asked to come in and fasting blood 
samples were taken to measure glucose levels. The dietary BCAA ratios in the obese 
participants were significantly lower than the non-obese participants. There was a negative 
correlation between the ratio of dietary BCAAs and BMI (r= -0.197, p<0.001) or waist 
circumference (r = -0.187, p<0.001). After stratification by gender, the significance of the 
dietary BCAA ratio for overweight/obesity existed for the 3rd and 4th quartiles (before 
stratification by gender OR, 0.508[95% CI 0.265-0.972] and 0.389[95%CI 0.193-0.783] 
respectively). The study found that the dietary BCAA ratio was inversely associated with BMI. 
There are possible biases that arise with an internet study. Because studies have shown that 
obesity is correlated with an increase in BCAAs in the blood, it is possible that the participants 
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did not honestly answer the questions about their daily lives and could have answered with 
ideals of how they want to be perceived (23). 
Another study also looking at pathways related to insulin resistance suggested that insulin 
resistance is associated with alterations in skeletal muscle BCAA metabolism. BCAA 
measurements performed on skeletal muscle biopsies via gene expression and metabolomics 
analyses found that perturbed BCAA and fatty acid oxidation are found in insulin-resistant 
humans. The results showed two genes, MUT and ALDH6A1, were down-regulated in multiple 
steps in the pathway to insulin resistance. This study concluded that impaired BCAA catabolism 
might contribute to the development of insulin resistance by perturbing BCAA and fatty acid 
oxidation, suggesting that treatments targeting BCAA metabolism dysfunction could be 
promising for individuals with T2D (24). 
The Chen et al. study was conducted in China from 2005 to 2015 and predicted the 
potential to develop T2D in a Chinese population in a secondary analysis study. The study 
population was gathered from a longitudinal cohort study and a cross-sectional study and 
included 429 Chinese participants in various stages of developing diabetes. In this study, BCAA 
levels were measured via mass spectrometry. The 213 subjects with the risk of developing 
diabetes were followed for ten years as a longitudinal study and compared to 216 subjects in a 
cross-sectional study that encompassed metabolically healthy or unhealthy status. The authors 
discovered that five amino acids (leucine, isoleucine, valine, phenylalanine, and tyrosine) that 
were differentially expressed in the healthy lean, overweight/obesity and diabetes individuals, 
when tested using an AA and metabolic levels heat map, are predictive of the risk of future 
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diabetes. The longitudinal study showed that individuals who became diabetic during the 10-
year follow-up period had significantly elevated AA levels compared to baseline levels, which 
suggests that elevated AA levels are predictive of diabetes. Valine was shown to have increased 
by 251% during the development of diabetes in the longitudinal study. In the cross-sectional 
study, the AA levels progressively increased in the overweight/obese and diabetic subjects.  The 
study concluded that there was a close correlation between BCAA levels, insulin resistance and 
the development of diabetes and that BCAA levels can predict the development of diabetes 
(25).  
Zheng et al. conducted a meta-analysis study in 2016 that included three prospective 
cohort studies conducted between 1980 and 2012. The cohort studies included were the 
Nurses' Health Study (NHS), NHS II and the Health Professionals Follow-up Study. The main 
objective was to determine how BCAA dietary intake affects the risk of T2D. There were 16,097 
incidents of T2D during the 32 years of follow-up. After adjustments for established risk factors, 
higher total BCAA intake was associated with an increased risk of T2D. All of the tests for linear 
trends across increasing BCAA quintiles were shown to be significant (p<0.005). Leucine, 
Isoleucine and Valine intake showed a 13% [HR (95% CI) 1.13 (1.05-1.22)], 8%, [1.08 (0.99-1.18)] 
and 15% [1.15 (1.03-1.29)] higher risk of T2D compared to the lowest AA intake, respectively. 
Stratification for diabetes risk factors, such as obesity, did not modify the associations between 
BCAAs and diabetes. The analysis concluded that high BCAA consumption is associated with an 
increased risk of T2D; moreover, these results were similar to many other studies (26). 
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Lee et al. conducted a secondary analysis using data from the Insulin Resistance 
Atherosclerotic Study, a cohort study conducted in the United States with recruitment between 
1992 and 1994 and specific analysis conducted in 2015 (9). The study recruited 1,625 
participants and only included 685 non-diabetic participants of Caucasian, African American, 
and Hispanic descent. Each participant had their plasma BCAA sum measured by mass 
spectrometry. Additionally, insulin sensitivity (Si), acute insulin response (AIR), and metabolic 
clearance rate of insulin (MCRI), which are factors that describe insulin clearance and glucose 
effectiveness, were also determined. Insulin sensitivity was measured using the Frequently 
Sampled Intravenous Glucose Tolerance methodology. The study examined associations 
between BCAAs and these indices of insulin resistance. After adjusting for potential 
confounders, the study found an inverse relationship between plasma BCAA levels and insulin 
sensitivity and MCRI (b = -0.0012 [95% CI -0.0018, -0.0059], P< 0.001 for Si; b= -0.0013 [95% CI -
0.0018, -0l.00082] P<0.001 for MCRI) and a positive association with fasting insulin (b=0.0015 
[95% CI 0.0008, 0.0023] P<0.001 for fasting insulin). Being of Caucasian or Hispanic descent was 
found to be significantly associated with Si. The adjusted odds ratio for plasma BCAAs was 1.67 
[95% CI 1.21, 2.29, P=0.02], though there was no significance in African Americans (8). These 
data suggested that race is a potential factor in BCAA levels, though other studies have proven 
otherwise (8). The results from this cohort study suggest that increased BCAA levels lead to 
lower insulin sensitivity, which subsequently promotes insulin resistance and T2D (27). 
McCormick et al. observed a younger population in their secondary analysis study. The 
study was conducted in the United States from 2007 to 2009 to understand whether pediatric 
obesity is associated with an increase in future insulin resistance. The participants are chosen 
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from a completed prospective cohort for 18 months. Sixty-nine healthy participants were 
selected from a cross-sectional study. BCAA levels were measured through mass spectrometry, 
and BMI and insulin resistance were measured from blood samples. Increases in BCAAs were 
significantly associated with BMI (rho =0.27, P=0.03) in the cross-sectional cohort. The goal of 
the study was to observe whether obesity is associated with future insulin resistance in children 
and adolescents. Obese children had higher BCAA concentrations (p=0.008), though there was 
not a significant association between BCAA concentrations and baseline insulin resistance. The 
study concluded that obesity in children is associated with elevated BCAA concentrations and 
that both of these characteristics are independently associated with future insulin resistance 
(28). 
Considering that BCAA levels are suggestive of predicting insulin resistance, Wurtz et al. 
conducted a study in young adults. This study was conducted in urban and rural areas in 
Finland. The first survey was given in 1980 and included children and adolescents between the 
ages of 3 and 18. Participants attended a follow-up in 2001, which was used as a baseline and 
ended in 2007. There was a total of 1,809 participants that were eligible for this prospective 
cohort study. Insulin resistance was calculated by HOMA-IR after fasting plasma insulin levels 
were determined from drawn blood, and BCAA levels were quantified by NMR. The 6-year 
follow-up found that the sum of the BCAA and Aromatic amino acid (AAA) concentrations were 
associated with insulin resistance in men (odds ratio 2.09[95%CI 1.38,3.17]; P=0.0005).  There 
were 168 individuals that were classified as insulin-resistant at follow-up.  After a 6-year follow-
up, insulin resistance was calculated by the homeostasis model assessment (HOMA) at baseline 
and concluded that isoleucine, leucine, valine, phenylalanine, and tyrosine were with insulin 
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resistance for men. In contrast, only valine, leucine, and phenylalanine were predictors for IR in 
women. BCAAs and AAAs are markers for the development of insulin resistance in young, non-
diabetic adults. They also find that BCAAs and AAAs predict the risk of T2D that is partially 
mediated through insulin resistance (29). 
Chapter 3: What is Unknown about BCAA  
 All of the studies discussed here were focused on whether BCAA metabolism is causal 
for insulin resistance or T2D. However, to date, it is not well understood whether adipose 
tissues alter BCAA metabolism during insulin resistance. There is evidence that BCAA 
catabolism is altered in obesity, which increases BCAA-derived acyl carnitines and therefore 
promotes obesity and insulin resistance. However, the question remains, are changes in BCAAs 
causal or just a biomarker that can potentially predict the development of T2D (1,12).  
There are many pathways and mechanisms that have been hypothesized, but there 
have not been any concrete conclusions on which mechanism is correct. Currently, there are no 
preventative methods that specifically target BCAAs, though exercise and having a healthy diet 
has been shown to decrease BCAA levels (1,2). Body-builders and people that enjoy working 
out take BCAA supplements and have positive effects; however, there is no clarification on 
whether these supplements can lead to insulin resistance. Because this is a biological issue, 
identifying a preventative method could potentially be difficult. So far, all of the studies in this 
review have examined the effects of elevated BCAA levels; however, it is not determined 
whether the elevated BCAA levels are high enough to be toxic to the body. Additionally, there 
are not recommendations for defining what are safe BCAA levels in the body. Therefore, more 
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studies should be conducted on whether BCAA levels can be high enough to promote toxicity 
and negative effects. 
 
Chapter 4: Recommendations and Conclusions 
4.1 Recommendations 
 Because there is still controversy regarding whether BCAA metabolism is a causal or 
predictive factor for T2D and insulin resistance, understanding what would be considered toxic 
levels of BCAAs and BCAA metabolites would be beneficial for future studies. A long-term 
longitudinal study on healthy exercise enthusiasts who take BCAA supplement and test whether 
this supplementation leads to insulin resistance could examine whether increased BCAAs have 
lasting effects. This study would require the investigators to follow the participants and perform 
routine blood and glucose tolerance tests over a long period to examine BCAA levels and insulin 
sensitivity over time. A baseline muscle biopsy and follow-up biopsy would be beneficial to test 
gene expression to further understand the contributions of the two BCAA mechanisms 
proposed earlier. Having a better understanding of these mechanisms would also be beneficial 
regarding how to treat individuals that are insulin-resistant, especially if BCAAs are determined 
to be a causal factor for the development of T2D.  
Another proposed study could focus on BCAA and BCAA by-product levels and how they 
affect the development of metabolic disorders. Compared to the studies performed in this 
review, this study would be more biochemically focused, but would also benefit from 
epidemiological analyses of the tested patients for determining correlations between specific 
genes and the risk/development of obesity, insulin resistance, and/or T2D.  This study could 
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examine varying BCAA and BCAA by-product levels on the development metabolic disorder by 
combining next-generation sequencing approaches and proteomics to look at the levels of 
various genes and proteins, respectively, in a variety of patients with different ages, exercise 
habits, diets, and body types as well as having different ethnic origins. Then, the generated data 
be annotated with Gene Ontology (GO) or the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) analysis to determine the types of genes and/or pathways that are enriched/affected 
with changes in BCAA levels.  This analysis could identify substantial correlations between 
BCAAs and their by-products with relevant cellular pathways; risk factors for obesity, insulin 
resistance, and T2D; and a variety of potential metabolic disorders, while also suggesting 
methods/mechanisms that could prevent disease development and promote healthy lifestyles. 
4.2 Conclusions 
In conclusion, although there are numerous studies that have shown associations 
between branched-chain amino acids and obesity, insulin resistance, and type 2 diabetes, it 
remains unclear whether BCAA levels are a causative factor that promotes these conditions. 
Several mechanisms have been postulated regarding the roles that BCAAs play in the metabolic 
pathways that lead to diabetes. However, most of these mechanisms have yet to be confirmed, 
suggesting that more in-depth research is necessary. Regardless, several studies support that 
idea that increased BCAA levels have the potential to be a biomarker for the loss of insulin 
effectiveness. 
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Table 1. Summary of Current Studies on BCAA 
Author Type of Study Population 
studied 
Sample Size Outcome 
Measures 
Conclusions 
Newgard 
et al.19,20 
Interventiona
l 
 
 
 
Experimental 
Wistar Rats 
 
 
 
Adults that are 
“healthy” 
Rats given a 
high fat diet, 
high fat and 
BCAA 
supplement 
or standard 
chow 
 
73 obese and 
67 lean 
subjects  
Rats with 
HF/BCAA 
rats were 
equally 
resistant as 
HF rats 
 
 
Wilcoxon 
rank sum 
test and PCA 
found BCAA 
positively 
correlated 
with HOMA 
r=0.58 
High fat 
consumption 
and poor 
diet, BCAA 
contributes 
to 
development 
of obesity-
associated 
insulin 
resistance 
Lackey et 
al.8 
Experimental Obese rats with 
white adipose 
tissue 
Fa/fa rats, 
db/db mice, 
diet induced 
obese mice 
BCKD 
expression 
was reduced 
35-50% in 
obesity 
models and 
that BCKD 
component 
transcripts 
were 
significantly 
lower in 
subcutaneou
s adipocytes 
compared to 
lean Pima 
Indians. 
Obesity is 
less 
important 
than WAT 
metabolic 
regulators in 
BCAA 
catabolism 
Cavallaro 
et al.3 
Interventiona
l 
Healthy males 5 healthy 
males  
Fasting BCAA 
were found 
to be 
significantly 
lower in 
valine 
(p=0.02) 
Short term 
dietary 
manipulation 
of BCAA 
intake led to 
modest 
changes in 
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fasting levels 
of BCAAs 
Lotta et 
al.13 
Case Study Individuals 
identified with 5 
genomic regions 
where genetic 
variants were 
associated with 
BCAA levels 
1,992 incident 
cases of T2D 
and 4,319 
non-cases  
Meta-
analysis 
found that 
stronger 
associations 
between 
higher level 
of each 
BCAA and 
higher risk of 
T2D 
Large-scale 
human 
genetic and 
metabolic 
study is 
consistent 
with a causal 
role of BCAA 
metabolism 
of T2D 
Shah et 
al.25 
Interventiona
l 
Adults 
participating in 
the Weight Loss 
Maintenance 
trial  
1053 WLM 
participants 
for Phase 1 
and 500 
participants 
in Phase 2 
PCA and 
mixed 
models 
BCAA 
correlated 
with 
baseline 
HOMA-IR  
(r=0.50, 
p<0.0001) 
and 
independent
ly with 
change 
HOMA-IR 
(p<0.0001) 
BCAA and 
related 
analytes 
predicts 
improvement
s in HOMA-IR 
independent 
of weight lost 
Lips et 
al.12 
Interventiona
l 
Obese women 
with and without 
T2D  
30 obese 
normal 
glucose 
tolerant, 32 
obese 
subjects with 
T2D and 12 
lean female 
subjects 
PCA revealed 
a correlation 
between 
BCAA and 
insulin 
sensitivity 
and glucose 
tolerance.  
There is an 
association 
between the 
deregulation 
of BCAA and 
insulin 
resistance. 
Bypass RYGB 
surgery, is 
independent 
of weight-
loss or 
presence of 
T2D, reduces 
BCAA levels 
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in obese 
subjects  
Qin et 
al.23 
Cross 
Sectional  
Adults in the 
International 
Study of 
Macro/Micronut
rients and Blood 
Pressure in 
China, Japan, UK 
and US  
4429 middle-
aged men and 
women 
between the 
ages 40-59 
years 
Multivariabl
e OR (95% 
CI) of dietary 
BCAA intake 
2nd -4th 
quartile 0.97 
(0.80-1.17), 
0.91 (0.75-
1.11) and 
0.70 (0.57-
0.86). BCAA 
intake and 
obesity are 
inversely 
associated 
(P-trend = 
0.03) 
Higher 
dietary BCAA 
intake is 
associated 
with lower 
prevalence of 
overweight 
status/obesit
y among 
health 
middle-aged 
adults from 
East Asia and 
Western 
countries. 
Li et al.11 Cross-
sectional 
Young Northern 
Chinese Adults 
between the 
ages 18-40 that 
completed the 
internet study, 
non-diabetic, 
and not on a diet 
in the past 6 
months 
948 randomly 
recruited 
participants 
and 90 
subjects 
recruited to 
explore a 
mechanism 
Multivariabl
e OR (95% 
CI) of dietary 
BCAA ratio 
with obesity 
of 3rd and 4th 
quartile 
0.351 (0.145-
0.845) and 
0.376 (0.161-
0.876) all 
with p<0.05. 
Higher ratio 
of dietary 
BCAA is 
inversely 
associated 
with 
prevalence of 
obesity and 
status of 
inflammation 
in young 
northern 
Chinese 
adults 
Lerin et 
al.10 
Cross 
sectional 
Humans with 
normal glucose 
tolerance and 
Type 2 diabetes 
41 humans 
with Normal 
Glucose 
Tolerance and 
11 with T2D  
Perturbed 
BCAA 
metabolism 
and fatty 
acid 
oxidation in 
muscle from 
insulin 
resistant 
humans 
Impaired 
muscle BCAA 
catabolism 
may 
contribute to 
the 
development 
of IR  
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Chen et 
al.4 
Cross-
sectional and 
Longitudinal 
cohort study 
Chinese adults at 
various stages of 
diabetes 
development 
429 Chinese 
participants  
213 with the 
risk of 
developing 
diabetes in 
the 
longitudinal 
study and 216 
healthy 
individuals in 
the cross-
sectional 
study 
Logistic 
regression 
model with 5 
AAs with risk 
of diabetes 
p-values 
≤0.001 
The 5 AAs are 
predictive of 
the risk of 
future 
diabetes as a 
marker for 
diabetes not 
causal. 
Zheng et 
al.30 
Prospective 
cohort 
Men and women 
at risk for T2D 
living in the US 
16,097 men 
and women 
incident T2D 
events during 
up to 32-year 
follow-up  
Meta-
analysis of all 
cohorts with 
hazard ratios 
for leucine 
1.13 (1.07-
1.19), 
isoleucine 
1.13 (1.07-
1.19), and 
valine 1.11 
(1.05-1.17) 
P-trend 
<0.001 
High 
consumption 
of BCAAs is 
associated 
with an 
increased risk 
of T2D 
Lee et 
al.9 
Secondary 
analysis 
Cohort  
Adults without 
diabetes in the 
Insulin 
Resistance 
Atherosclerosis 
Study in 4 
clinical location 
in the US  
685 men and 
women. 290 
Caucasians, 
165 African 
American, 
and 230 
Hispanics. 
Regression 
models 
found 
elevated 
plasma BCAA 
were 
inversely 
associated 
with Si and 
positively 
with fasting 
insulin. Si (B= 
-0.0012 (-
0.0018—
0.00059) 
fasting 
Plasma BCAA 
are 
associated 
with incident 
diabetes and 
underlying 
metabolic 
abnormalitie
s. 
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insulin 
(B=0.0015 
(0.0008-
0.0023) 
McCorma
ck et al.17 
Cross-
sectional and 
Longitudinal 
Cohort 
Children and 
adolescents in 
Boston that are 
pre- or early 
pubertal. 
69 healthy 
subjects 
between 8-18 
years old and 
a subset of 17 
participants 
for a 
longitudinal 
cohort 
Using a 
spearman 
correlation 
r=0.27, 
p=0.03 find 
that there is 
a correlation 
between 
BCAA and 
BMI in the 
cross-
sectional 
study and 
longitudinal 
cohort. 
Elevated 
concentratio
ns of 
circulating 
BCAA are 
significantly 
associated 
with obesity 
in children 
and 
adolescents 
and may 
predict 
insulin 
resistance.  
Wurtz et 
al.27 
Prospective 
Cohort  
Young adults in 
the 
Cardiovascular 
Risk in young 
Finns Study  
1680 non-
diabetic 
young adults  
Linear 
regression 
models 
found that 
BCAA is 
associated 
with insulin 
resistance 
OR 2.09 
(CI=1.38-
3.17) 
BCAA are 
markers of 
the 
development 
of IR in young 
nonglycemic 
adults.  
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